Table 2 Association between the clinicopathological characteristics and survival outcome
From: Upregulation of SLC2A3 gene and prognosis in colorectal carcinoma: analysis of TCGA data
Overall survival | Disease-free survival | |||||
|---|---|---|---|---|---|---|
Non-event | Event | P valuea | Non-event | Event | P valuea | |
Age | ||||||
< = 65 | 141 | 23 | < 0.001 | 115 | 43 | 1 |
> 65 | 126 | 55 | 107 | 40 | ||
Sex | ||||||
Female | 124 | 33 | 0.606 | 103 | 34 | 0.472 |
Male | 143 | 45 | 119 | 49 | ||
AJCC TNM stage | ||||||
I and II | 157 | 27 | < 0.001 | 137 | 32 | < 0.001 |
III and IV | 110 | 51 | 85 | 51 | ||
MSI | ||||||
MSI-L and MSS | 224 | 67 | 0.802 | 184 | 72 | 0.520 |
MSI-H | 43 | 11 | 38 | 11 | ||
BRAF status | ||||||
Wild-type | 230 | 65 | 0.662 | 188 | 74 | 0.416 |
Mutant | 37 | 13 | 34 | 9 | ||
KRAS status | ||||||
Wild-type | 154 | 47 | 0.783 | 133 | 43 | 0.252 |
Mutant | 113 | 31 | 89 | 40 | ||